Published:
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies
announced today the results of Phase I/II and II studies of Rexin-G in
chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as
presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th
annual meetings held inLondon UK on November 13-15, 2008. Patients received
repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of
safety and efficacy data showed no major toxicity, while documenting
significant control of tumor growth.
Analysis of efficacy in 42 patients with bone and soft tissue sarcoma
showed a dose-response relationship between overall survival and Rexin-G which
was highly significant. A confirmatory Phase II study in 17 osteosarcoma
patients showed a median overall survival greater than seven months; that is,
after failing standard chemotherapies. Two patients are disease-free greater
than 6 months after surgical resection of residual tumors and Rexin-G given as
both neoadjuvant and adjuvant monotherapy. These studies indicate that (i)
intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls
tumor growth and improves survival in a dose-dependent manner in patients with
chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical
company dedicated to the advancement of genetic medicine with the development
and commercialization of its proprietary targeted delivery systems. To learn
more about Rexin-G and Epeius Biotechnologies' pipeline of proprietary
compounds currently available for clinical development, please visit us at
http://www.epeiusbiotech.com .
*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)
This release was issued on behalf of the above organization by
Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
SOURCE Epeius Biotechnologies
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,MTC,HEA,TRI,TDS,CA-Epeius-Biotechnol
_ _
Breast Cancer News
Search News
Daily News
